Literature DB >> 18633695

Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.

Matthew L Zierhut1, Marc R Gastonguay, Steven W Martin, Paolo Vicini, Pirow J Bekker, Donna Holloway, Philip T Leese, Mark C Peterson.   

Abstract

Osteoporosis is a metabolic bone disease resulting from increased bone resorption and characterized by low bone mass that leads to increased bone fragility and risk of fracture, particularly of the hip, spine and wrist. Bone resorption is dependent on receptor activator of NF-kappa B ligand (RANKL), which binds to RANK receptor on preosteoclasts to initiate osteoclastogenesis and maintains osteoclast function and survival. To neutralize the effects of RANKL, the body naturally produces the protein osteoprotegerin (OPG), which acts as a decoy receptor for RANKL and contributes to bone homeostasis. We describe the piecewise development of a three-compartment pharmacokinetic model with both linear and Michaelis-Menten eliminations, and an indirect pharmacodynamic response model to describe the pharmacokinetics and pharmacodynamics, respectively, of the fusion protein, Fc-osteoprotegerin (Fc-OPG), in healthy postmenopausal women. Subsequently, model verification was performed and used to address study design questions via simulation. The model was developed using data from eight cohorts (n = 13 subjects/cohort; Fc-OPG:placebo = 10:3) classified by dose level (0.1, 0.3, 1.0, or 3.0 mg/kg) and route of administration (intravenous [IV] or subcutaneous [SC]). Fc-OPG serum concentrations and urinary N-telopeptide/creatinine ratios (NTX) following both IV and SC administration were available. The model provided an adequate fit to the observed data and physiologically plausible parameter estimates. Model robustness was tested via a posterior predictive check with the model performing well in most cases. Subsequent clinical trial simulations demonstrated that a single 3.0-mg/kg SC dose of Fc-OPG would be expected to produce, at 14 days post-dose, a median NTX percentage change from baseline of -45% (with a 95% prediction interval ranging from -34% to -60%). Lastly, model ruggedness was evaluated using local and global sensitivity analysis methods. In conclusion, the model selection and simulation strategies we applied were rigorous, useful, and easily generalizable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633695     DOI: 10.1007/s10928-008-9093-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

1.  Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models.

Authors:  I A Nestorov
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 3.  Biomarkers in drug discovery and development: from target identification through drug marketing.

Authors:  Wayne A Colburn
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

Review 4.  The anabolic effects of parathyroid hormone therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Clin Geriatr Med       Date:  2003-05       Impact factor: 3.076

5.  The effect of a single dose of osteoprotegerin in postmenopausal women.

Authors:  P J Bekker; D Holloway; A Nakanishi; M Arrighi; P T Leese; C R Dunstan
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

6.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

Authors:  Goonaseelan Pillai; Ronald Gieschke; Timothy Goggin; Philippe Jacqmin; Ralph C Schimmer; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

7.  A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.

Authors:  Serge Cremers; Rolf Sparidans; Hartigh Jan den; Neveen Hamdy; Pieter Vermeij; Socrates Papapoulos
Journal:  Eur J Clin Pharmacol       Date:  2002-02       Impact factor: 2.953

Review 8.  Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.

Authors:  Karen S Blesch; Ronald Gieschke; Yuko Tsukamoto; Bruno G Reigner; Hans U Burger; Jean-Louis Steimer
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 9.  New approaches to pharmacological treatment of osteoporosis.

Authors:  Kristina Akesson
Journal:  Bull World Health Organ       Date:  2003       Impact factor: 9.408

10.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

View more
  3 in total

1.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

2.  Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study.

Authors:  Yuyan Jin; Robert Bies; Marc R Gastonguay; Yaning Wang; Norman Stockbridge; Jogarao Gobburu; Rajanikanth Madabushi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-18       Impact factor: 2.745

Review 3.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.